New York University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Memorial Sloan Kettering Cancer Center

Other

Cornell University

Aaron Diamond Aids Research Center

Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana (fisabio)

Dan R Littman

Jun R Huh

Hongkui Deng

Wenwei Huang

Ruili Huang

Nicolas Manel

Nathaniel R Landau

Rong Liu

Erika Elaine Englund

Wilfried Ellmeier

Eric G Pamer

Steven B Abramson

Derya Unutmaz

Carles Ubeda

Vineet N Kewalramani

Randy S Longman

Jose U Scher

David Y Gin

Michael R Krout

Sang-Won Kim

Sergei B Koralov

Teunis Geijtenbeek

Yvette Van Kooyk

Douglas Kwon

Gretchen E Diehl

Daniel A Ryan

Michael Fischbach

Andrew Sczesnak

Jhimmy Talbot

Nicolas Gabriel Albert Manel

Steroid compounds are disclosed that have a formula represented by the following: (I) and wherein R, R, R, R, R, R, R, R, R, R, R, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for promoting differentiation of T regulatory (Treg) lymphocytes, and for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, and graft-versus-host disease.

Steroid compounds as Treg modulators and uses thereof

Provided are compositions and methods for maintaining intestinal immune homeostasis. The method comprises administering to an individual an effective amount of a VIPR2 inhibitor. The method may modulate gut resident CCR6ILC3 cell function.

Vasointestinal peptide receptor inhibitors for enhancement of gastrointestinal health

Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R, R, R, R, R, R, and Rare as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Amido compounds as ROR&#x3b3;t modulators and uses thereof

Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.

Methods for treating psoriatic arthritis

Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.

Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody

Methods are presented herein for reducing the risk of developing a psychiatric disorder (e.g., autism like disorder) in a fetus involving administering an inhibitor of T helper 17 (Th17) cell activity to the mother of the fetus, while the mother is pregnant with the fetus at risk. Also encompassed herein is a method for treating a fetus in utero to reduce the risk of abnormal cortical development that arises from Th17 cell-mediated activity.

Maternal TH17 cells and psychiatric disorders

Methods, reagents and compositions thereof for predicting RA onset in susceptible individuals, diagnosing RA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of a particular bacterial species comprising SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 (SEQ ID NO: 1+ bacteria) serves as a biomarker for the above indications.

Causative agents and diagnostic methods relating to rheumatoid arthritis

Amido compounds are disclosed that have a formula represented by the following: and wherein Cy, Cy, n1, n2, R, R, R, R, R, R, and Rare as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Steroid compounds are disclosed that have a formula represented by the following: and wherein m, n, t, u1, u2, v1, v2, R, R, R, R, R, R, R, R, and Y are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the treatment or prevention of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Steroid compounds as RORyt modulators and uses thereof

The present invention is directed to an in vitro method for promoting differentiation and proliferation of human T helper lymphocytes that express IL17 (Th-IL17+ cells). The instant method may be used to generate a population of human T helper lymphocytes that express IL17 (Th-IL17+ cells) in vitro. Methods for screening to identify agents capable of modulating Th-IL17+ cell differentiation are also encompassed by the present invention. Isolated, pure populations of homogeneous Th-IL17+ cells that do not express cellular markers characteristic of Th1, Th2, or Treg cells are also encompassed herein.

Methods for in vitro differentiation of TH-17+ cells

The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes.

GPR15-mediated homing and uses thereof

The present invention relates to enhancing, modulating or stimulating the innate immune response to HIV-1 and other viral pathogens and to the modulation and application of immune modulators and peptides for HIV-1 or other pathogen vaccines. The invention provides methods and means to activate an innate response to HIV-1 utilizing or via the HIV capsid protein or peptide, including modulating the binding of cyclophilin A to HIV capsid protein and modulating the ability of HIV to activate the major innate transcription factor IRF3 and interferon. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating innate immune response, particularly to HIV-1.

Methods, agents and peptides for inducing an innate immune response in HIV vaccination

Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR&#x3b3;t modulators that have a formula represented by the following: and wherein n1, n2, R, R, R, and Rare as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Growing community of inventors

New York, NY, United States of America

Dan R Littman